Ask AI
ProCE Banner Activity

CME

What’s Next in SCLC: Expert Perspectives on Practice-Changing Updates From 2025 Global Congresses

Video

In this certified on-demand webcast, experts review evolving standards of care and emerging clinical trial data shaping the management of limited- and extensive-stage small-cell lung cancer (SCLC), including the integration of immunotherapy, novel agents, and strategies to optimize patient outcomes.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: May 12, 2026

Expiration: November 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational funding provided by Amgen and Boehringer Ingelheim Pharmaceuticals, Inc.

Amgen

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for patients with small cell lung cancer. 

Program Learning Goal

The goal of this activity is to improve learners’ knowledge and clinical competence by equipping them with the most recent evidence to support the application of emerging treatment strategies, biomarker insights, and safety considerations into the personalized care of patients with small cell lung cancer across all stages and lines of therapy. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize key efficacy and safety findings from the 2025 ASCO, ESMO, and WCLC meetings that inform first-line and maintenance treatment decisions for patients with limited-stage and extensive-stage SCLC

  • Evaluate the role of immunotherapy in the evolving management of limited-stage and extensive-stage SCLC, including new evidence supporting consolidation or maintenance strategies

  • Analyze recent data on lurbinectedin, DLL3-targeted bispecific antibodies, and antibody–drug conjugates to support optimal sequencing strategies for patients with relapsed/refractory SCLC

  • Interpret emerging biomarker evidence, such as SLFN11 and DLL3 expression, to determine its potential role in treatment personalization for patients with SCLC

  • Apply clinical best practices for mitigating immune-related and agent-specific adverse events associated with novel agents in the SCLC treatment landscape

  • Integrate new evidence into individualized treatment plans by considering performance status, comorbidities, and quality-of-life considerations across lines of therapy

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Charles Rudin, MD, PhD: consultant: AbbVie, Amgen, Daiichi Sankyo, Genentech, Merck, Novartis.

Mark A. Socinski, MD: consultant/advisor/speaker: AstraZeneca.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 12, 2026, through November 11, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.